{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:08:06Z","timestamp":1773839286040,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T00:00:00Z","timestamp":1417824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00467-014-3006-1","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T08:16:20Z","timestamp":1417767380000},"page":"1909-1918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fibroblast growth factor 23 and acute kidney injury"],"prefix":"10.1007","volume":"30","author":[{"given":"Javier A.","family":"Neyra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orson W.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Chang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,6]]},"reference":[{"key":"3006_CR1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","volume":"75","author":"MC Hu","year":"2013","unstructured":"Hu MC, Shiizaki K, Kuro-o M, Moe OW (2013) Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75:503\u2013533","journal-title":"Annu Rev Physiol"},{"key":"3006_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/dvdy.21388","volume":"237","author":"N Itoh","year":"2008","unstructured":"Itoh N, Ornitz DM (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237:18\u201327","journal-title":"Dev Dyn"},{"key":"3006_CR3","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687\u201326695","journal-title":"J Biol Chem"},{"key":"3006_CR4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","volume":"22","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T (2008) betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22:1006\u20131014","journal-title":"Mol Endocrinol"},{"key":"3006_CR5","doi-asserted-by":"crossref","first-page":"33304","DOI":"10.1074\/jbc.M803319200","volume":"283","author":"X Wu","year":"2008","unstructured":"Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, Tian H, Li Y (2008) C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 283:33304\u201333309","journal-title":"J Biol Chem"},{"key":"3006_CR6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345\u2013348","journal-title":"Nat Genet"},{"key":"3006_CR7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-009-1273-z","volume":"25","author":"J Gattineni","year":"2010","unstructured":"Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591\u2013601","journal-title":"Pediatr Nephrol"},{"key":"3006_CR8","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297:F282\u2013F291","journal-title":"Am J Physiol Renal Physiol"},{"key":"3006_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125\u2013131","journal-title":"J Endocrinol"},{"key":"3006_CR10","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1152\/ajprenal.00740.2010","volume":"301","author":"J Gattineni","year":"2011","unstructured":"Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M (2011) Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 301:F371\u2013F377","journal-title":"Am J Physiol Renal Physiol"},{"key":"3006_CR11","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","volume":"145","author":"T Larsson","year":"2004","unstructured":"Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087\u20133094","journal-title":"Endocrinology"},{"key":"3006_CR12","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1210\/en.2004-0233","volume":"145","author":"X Bai","year":"2004","unstructured":"Bai X, Miao D, Li J, Goltzman D, Karaplis AC (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269\u20135279","journal-title":"Endocrinology"},{"key":"3006_CR13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ajmg.a.36476","volume":"164A","author":"G Finer","year":"2014","unstructured":"Finer G, Price HE, Shore RM, White KE, Langman CB (2014) Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. Am J Med Genet A 164A:1545\u20131549","journal-title":"Am J Med Genet A"},{"key":"3006_CR14","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408","journal-title":"J Clin Invest"},{"key":"3006_CR15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427\u20131435","journal-title":"J Am Soc Nephrol"},{"key":"3006_CR16","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2215\/CJN.02640310","volume":"5","author":"OM Gutierrez","year":"2010","unstructured":"Gutierrez OM (2010) Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis. Clin J Am Soc Nephrol 5:1710\u20131716","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.05840513","volume":"9","author":"AA Portale","year":"2014","unstructured":"Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB (2014) Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 9:344\u2013353","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfs460","volume":"28","author":"I Pavik","year":"2013","unstructured":"Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wuthrich RP, Russmann S, Serra AL (2013) Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 28:352\u2013359","journal-title":"Nephrol Dial Transplant"},{"key":"3006_CR19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656\u20131663","journal-title":"N Engl J Med"},{"key":"3006_CR20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770\u2013774","journal-title":"Nature"},{"key":"3006_CR21","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281:6120\u20136123","journal-title":"J Biol Chem"},{"key":"3006_CR22","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfu190","volume":"29","author":"GS Marco Di","year":"2014","unstructured":"Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstadt H, Wolf M, Faul C, Brand M (2014) Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 29:2028\u20132035","journal-title":"Nephrol Dial Transplant"},{"key":"3006_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0004563213510708","volume":"51","author":"ER Smith","year":"2014","unstructured":"Smith ER, McMahon LP, Holt SG (2014) Fibroblast growth factor 23. Ann Clin Biochem 51:203\u2013227","journal-title":"Ann Clin Biochem"},{"key":"3006_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ndt\/gfs411","volume":"28","author":"M Wan","year":"2013","unstructured":"Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R (2013) Fibroblast growth factor 23 and soluble Klotho in children with chronic kidney disease. Nephrol Dial Transplant 28:153\u2013161","journal-title":"Nephrol Dial Transplant"},{"key":"3006_CR25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378","journal-title":"Kidney Int"},{"key":"3006_CR26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22:956\u2013966","journal-title":"J Am Soc Nephrol"},{"key":"3006_CR27","doi-asserted-by":"crossref","first-page":"e93423","DOI":"10.1371\/journal.pone.0093423","volume":"9","author":"I Six","year":"2014","unstructured":"Six I, Okazaki H, Gross P, Cagnard J, Boudot C, Maizel J, Drueke TB, Massy ZA (2014) Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One 9:e93423","journal-title":"PLoS One"},{"key":"3006_CR28","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","volume":"307","author":"N Silswal","year":"2014","unstructured":"Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, Stubbs JR, Wacker MJ (2014) FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 307:E426\u2013E436","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3006_CR29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.08680811","volume":"7","author":"C Nakano","year":"2012","unstructured":"Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7:810\u2013819","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR30","doi-asserted-by":"crossref","unstructured":"Zhang M, Hsu R, Hsu CY, Kordesch K, Nicasio E, Cortez A, McAlpine I, Brady S, Zhuo H, Kangelaris KN, Stein J, Calfee CS, Liu KD (2011) FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 1:21","DOI":"10.1186\/2110-5820-1-21"},{"key":"3006_CR31","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2215\/CJN.00550112","volume":"7","author":"DE Leaf","year":"2012","unstructured":"Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, Stern L (2012) FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 7:1217\u20131223","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/cen.12172","volume":"79","author":"DE Leaf","year":"2013","unstructured":"Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I, Stern L (2013) Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf) 79:491\u2013498","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3006_CR33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00467-012-2395-2","volume":"28","author":"FN Ali","year":"2013","unstructured":"Ali FN, Hassinger A, Price H, Langman CB (2013) Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study. Pediatr Nephrol 28:959\u2013962","journal-title":"Pediatr Nephrol"},{"key":"3006_CR34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ki.2013.150","volume":"84","author":"M Christov","year":"2013","unstructured":"Christov M, Waikar SS, Pereira RC, Havasi A, Leaf DE, Goltzman D, Pajevic PD, Wolf M, Juppner H (2013) Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 84:776\u2013785","journal-title":"Kidney Int"},{"key":"3006_CR35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2215\/CJN.05830513","volume":"9","author":"JR Brown","year":"2014","unstructured":"Brown JR, Katz R, Ix JH, de Boer IH, Siscovick DS, Grams ME, Shlipak M, Sarnak MJ (2014) Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol 9:239\u2013246","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR36","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/ndt\/gfp682","volume":"25","author":"DE Leaf","year":"2010","unstructured":"Leaf DE, Wolf M, Stern L (2010) Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. Nephrol Dial Transplant 25:1335\u20131337","journal-title":"Nephrol Dial Transplant"},{"key":"3006_CR37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204","journal-title":"Crit Care"},{"key":"3006_CR38","doi-asserted-by":"crossref","first-page":"e70775","DOI":"10.1371\/journal.pone.0070775","volume":"8","author":"C Zanchi","year":"2013","unstructured":"Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C (2013) Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One 8:e70775","journal-title":"PLoS One"},{"key":"3006_CR39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2215\/CJN.09020911","volume":"7","author":"I Pavik","year":"2012","unstructured":"Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wuthrich RP, Schmid C, Serra AL (2012) Soluble Klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:248\u2013257","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ki.2010.375","volume":"79","author":"I Pavik","year":"2011","unstructured":"Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wuthrich RP, Serra AL (2011) Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 79:234\u2013240","journal-title":"Kidney Int"},{"key":"3006_CR41","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ki.2013.526","volume":"85","author":"D Spichtig","year":"2014","unstructured":"Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, Serra AL, Wagner CA (2014) Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 85:1340\u20131350","journal-title":"Kidney Int"},{"key":"3006_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/BJ20101825","volume":"434","author":"J Wang","year":"2011","unstructured":"Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434:365\u2013381","journal-title":"Biochem J"},{"key":"3006_CR43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.genom.1.1.75","volume":"1","author":"NC Andrews","year":"2000","unstructured":"Andrews NC (2000) Iron metabolism: iron deficiency and iron overload. Annu Rev Genomics Hum Genet 1:75\u201398","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"3006_CR44","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","volume":"341","author":"NC Andrews","year":"1999","unstructured":"Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986\u20131995","journal-title":"N Engl J Med"},{"key":"3006_CR45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23:411\u2013419","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3006_CR46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2013.12.001","volume":"60","author":"EA Imel","year":"2014","unstructured":"Imel EA, Gray AK, Padgett LR, Econs MJ (2014) Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone 60:87\u201392","journal-title":"Bone"},{"key":"3006_CR47","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541\u20133549","journal-title":"J Clin Endocrinol Metab"},{"key":"3006_CR48","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108:E1146\u2013E1155","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3006_CR49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ (2009) Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 46:167\u2013169","journal-title":"Ann Clin Biochem"},{"key":"3006_CR50","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2169\/internalmedicine.51.7450","volume":"51","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S, Okada Y, Mori H, Fukumoto S, Tanaka Y (2012) Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. Intern Med 51:2375\u20132378","journal-title":"Intern Med"},{"key":"3006_CR51","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG (2009) FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94:2332\u20132337","journal-title":"J Clin Endocrinol Metab"},{"key":"3006_CR52","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793\u20131803","journal-title":"J Bone Miner Res"},{"key":"3006_CR53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jbmr.2049","volume":"29","author":"EL Clinkenbeard","year":"2014","unstructured":"Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, White KE (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 29:361\u2013369","journal-title":"J Bone Miner Res"},{"key":"3006_CR54","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1681\/ASN.V10112396","volume":"10","author":"CL Davis","year":"1999","unstructured":"Davis CL, Kausz AT, Zager RA, Kharasch ED, Cochran RP (1999) Acute renal failure after cardiopulmonary bypass in related to decreased serum ferritin levels. J Am Soc Nephrol 10:2396\u20132402","journal-title":"J Am Soc Nephrol"},{"key":"3006_CR55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/ajkd.2003.50025","volume":"41","author":"KR Tuttle","year":"2003","unstructured":"Tuttle KR, Worrall NK, Dahlstrom LR, Nandagopal R, Kausz AT, Davis CL (2003) Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 41:76\u201383","journal-title":"Am J Kidney Dis"},{"key":"3006_CR56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrneph.2013.98","volume":"9","author":"AM Martines","year":"2013","unstructured":"Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW (2013) Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 9:385\u2013398","journal-title":"Nat Rev Nephrol"},{"key":"3006_CR57","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2215\/CJN.08340811","volume":"6","author":"SV Shah","year":"2011","unstructured":"Shah SV, Rajapurkar MM, Baliga R (2011) The role of catalytic iron in acute kidney injury. Clin J Am Soc Nephrol 6:2329\u20132331","journal-title":"Clin J Am Soc Nephrol"},{"key":"3006_CR58","doi-asserted-by":"crossref","first-page":"F426","DOI":"10.1152\/ajprenal.00248.2010","volume":"299","author":"AC Johnson","year":"2010","unstructured":"Johnson AC, Becker K, Zager RA (2010) Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 299:F426\u2013F435","journal-title":"Am J Physiol Renal Physiol"},{"key":"3006_CR59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, Kuro-o M, Mohammadi M (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107:407\u2013412","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3006_CR60","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3357\u20133365","journal-title":"J Clin Endocrinol Metab"},{"key":"3006_CR61","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578\u2013585","journal-title":"J Clin Endocrinol Metab"},{"key":"3006_CR62","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jor.20857","volume":"27","author":"S Goebel","year":"2009","unstructured":"Goebel S, Lienau J, Rammoser U, Seefried L, Wintgens KF, Seufert J, Duda G, Jakob F, Ebert R (2009) FGF23 is a putative marker for bone healing and regeneration. J Orthop Res 27:1141\u20131146","journal-title":"J Orthop Res"},{"key":"3006_CR63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1471-2369-14-281","volume":"14","author":"E Gravesen","year":"2013","unstructured":"Gravesen E, Hofman-Bang J, Mace ML, Lewin E, Olgaard K (2013) High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol 14:281","journal-title":"BMC Nephrol"},{"key":"3006_CR64","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","volume":"28","author":"S Wohrle","year":"2013","unstructured":"Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D (2013) Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28:899\u2013911","journal-title":"J Bone Miner Res"},{"key":"3006_CR65","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.mnh.0000447012.98357.da","volume":"23","author":"S Fukumoto","year":"2014","unstructured":"Fukumoto S (2014) Anti-fibroblast growth factor 23 antibody therapy. Curr Opin Nephrol Hypertens 23:346\u2013351","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3006_CR66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ndt\/gfs557","volume":"28","author":"M Ketteler","year":"2013","unstructured":"Ketteler M, Biggar PH, Liangos O (2013) FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 28:821\u2013825","journal-title":"Nephrol Dial Transplant"},{"key":"3006_CR67","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122:2543\u20132553","journal-title":"J Clin Invest"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-014-3006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-014-3006-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-014-3006-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T22:28:48Z","timestamp":1650752928000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-014-3006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,6]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s00467-014-3006-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,6]]}}}